A cross‐sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa ( PACT‐MEA ): Study design and rationale
Study context
- Population
- Patients with T2D and established ASCVD or high/very high ASCVD risk (2021 European Society of Cardiology Guidelines) in primary and secondary care in Bahrain, Egypt, Jordan, Kuwait, Qatar, South Africa and the United Arab Emirates; physicians treating patients with T2Dplanned ≈3700 patients
- Primary endpoint
- Prevalence of established atherosclerotic cardiovascular disease (eASCVD) and high/very high ASCVD risk in patients with T2D
Methodological detailsobservational, study design and rationale, medical chart review, physician survey, Planned: chart review of ≈3700 patients with T2D and survey of ≈400 physicians, Also assessed: cardioprotective antidiabetic medication use, proportion meeting reimbursement criteria, physician-reported decision-making factors
- Observational
- Study design and rationale
- Medical chart review
- Physician survey
- Planned: chart review of ≈3700 patients with T2D and survey of ≈400 physicians
- Also assessed: cardioprotective antidiabetic medication use, proportion meeting reimbursement criteria, physician-reported decision-making factors
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
A cross‐sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa ( PACT‐MEA ): Study design and rationale. Diabetes Obes Metab. Published 3 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →